


# arm research

outperform

HDFC BANK – Q2 FY12 Result Update	20 <sup>th</sup> October, 2011
BSE Code	500180
BSE Group / Index	A / SENSEX
CMP	Rs. 489.50
Market Capitalization	Rs. 114,310 Cr
Face Value	Rs.2
EPS (TTM)	Rs.19.25
Book Value per Share	Rs.110
52 Wk High (BSE)	Rs.519.50 (19 July,2011)
52 Wk Low (BSE)	Rs.396.00 (9 Feb,2011)

# Shareholding Pattern % as of Sep,2011



# Public holding more than 1% of the Total No. of Shares (as of Sep, 2011)

Sl. No.	Name of the Shareholder	No. of Shares	Shares as % of Total No. of Shares
1	Life Insurance Corporation of India	76,919,988	3.29
2	ICICI Prudential Life Insurance Company Ltd	59,083,310	2.53
3	Europacific Growth Fund	54,845,000	2.35
	Total	190,848,298	8.16



# **Q2 FY12 – Result Highlights**

Particulars (Rs.Cr)	Q2 FY12	Q1 FY12	QoQ (%)	Q2 FY11	YoY (%)	H1 FY12	H1 FY11	YoY (%)
Interest Earned	6717.70	5977.97	12.37%	4809.99	39.66%	12695.67	9229.70	37.55%
Interest Expended	3773.19	3130.01	20.55%	2283.72	65.22%	6903.20	4302.73	60.44%
Net Interest Income	2944.51	2847.96	3.39%	2526.27	16.56%	5792.47	4926.97	17.57%
Non-Interest Income	1211.68	1120.03	8.18%	960.71	26.12%	2332.71	1951.57	19.53%
<b>Total Income</b>	4156.19	3967.99	4.74%	3486.98	19.19%	8125.18	6878.54	18.12%
Operating Expenses	2030.39	1934.63	4.95%	1679.88	20.87%	3966.02	3322.73	19.36%
Operating Profit	2125.80	2033.36	4.55%	1807.10	17.64%	4159.16	3555.81	16.97%
Provisions & Contingencies	366.05	443.66	-17.49%	454.48	-19.46%	809.71	1009.50	- 19.79%
Profit before Tax	1759.75	1589.70	10.70%	1352.62	30.10%	3349.45	2546.31	31.54%
Tax	560.40	504.72	11.03%	440.48	27.22%	1065.12	822.46	29.50%
Profit after Tax	1199.35	1084.98	10.54%	912.14	31.49%	2284.33	1723.85	32.51%
Equity share capital (FV-Rs.2)	467.66	466.77		462.60		467.66	462.60	
EPS (Rs.)	5.13	4.65		3.94		9.77	7.45	

# arm research



outperform

#### Robust growth in advances fuels NII growth

The NII of the bank grew by 16.6% YoY and 3.4% QoQ to Rs2, 944 crore. This was majorly led by a strong growth in advances which grew by 20% YoY on a reported basis; however adjusted for the short-term one-off loans of last year, loan growth was healthy at 25%. The growth in advances was driven by the retail segment which grew 34% YoY and constituted approximately 50% of the advances. The deposits of the bank grew by 18.1% YoY and 9.2% QoQ.

### **Decline in CASA impacts margins**

HDFC Bank saw a sharp 170 bps QoQ decline in CASA to 47.3%. Management attributed this to higher traction in term deposits relative to savings deposits due to elevated interest rate levels and migration from savings to term deposits & admitted that CASA migration would continue in the near term which will restrict any material improvement in the ratio. Consequently margins also declined by 10bps QoQ to 4.1%. In the medium term, management expects NIM to move in the band of 3.9-4.3%.

### Non-interest income rises 26% YoY

The non-interest income of the bank grew by 26.1% YoY and 8.2% QoQ to Rs1,212 crore. The foreign exchange (forex) and trading income grew by a robust 43.1% YoY while fee income registered a moderate growth of 15.2% YoY due to sluggishness in distribution income. The loss on sale of investments was also lower at Rs.1.3Cr in Q2 FY12 as compared to a loss of Rs.52Cr in Q1 FY12.

#### Stable asset quality


The asset quality of the bank remained stable with gross and net NPAs at 1% and 0.2% respectively. The proportion of restructured advances stood at 0.4% of the total advances of which the standard restructured advances stood at 0.1%. Management expects gross NPAs ratio to revert to normalized levels of 1.3-1.5% from current 1% in the longer term. The provision coverage ratio declined to 81.3% in Q2 FY12 as compared to 83% in Q1 FY12.

"HDFC Bank seems to be a safe bet in the current challenging macro environment...."




# **Quarterly Trends**


# Asset quality remains best amongst peers



# Advances grow at 20% YoY




# Deposit grow at 18% YoY







# Stable NIMs, Declining CASA



# **Healthy capital adequacy**



# **Branch & ATMs expansion gaining traction**





# arm research

outperform

#### Disclaimer:

**Analyst Holding: Yes** 

Recommended to Clients: Yes Relationship with Management: No

Persons into whose possession this document may come are required to observe these restrictions. This material is for the personal information of the authorized recipient, and we are not soliciting any action based upon it. This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It is for the general information of clients and Associates of arm research. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. We have reviewed the report, and in so far as it includes current or historical information, it is believed to be reliable though its accuracy or completeness cannot be guaranteed. Neither arm research, nor any person connected with it, accepts any liability arising from the use of this document. The recipients of this material should rely on their own investigations and take their own professional advice. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions -including those involving futures, options and other derivatives as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Reports based on technical analysis centers on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. We and our affiliates, officers, directors, and employees may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential conflict of interest with respect to any recommendation and related information and opinions. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. No part of this material may be duplicated in any form and/or redistributed without arm research's prior written consent.

Contact us: research@armresearch.in

pr@armresearch.in

Tel No: 022- 26394073/97